# Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

> **NCT05660967** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 111 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05660967
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2026-06-14
- **Final completion:** 2026-06-28
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660967, "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05660967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*